This is an HTML version of an attachment to the Freedom of Information request 'Chemicals Strategy for Sustainability'.



   
From: 
 (CAB-KYRIAKIDES) 
Sent: 
mercredi 1 juillet 2020 11:14 
To: 
 (CAB-KYRIAKIDES); 
 (CAB-
KYRIAKIDES); 
 (CAB-KYRIAKIDES); 
 (CAB-KYRIAKIDES) 
Cc: 
 (CAB-KYRIAKIDES) 
Subject: 
Report from meeting with Endocrine Society (cancer, 
chemicals) 
Attachments: 
BTO ED society 30062020.doc 
FYI 




   
EUROPEAN COMMISSION 
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL 
Brussels, 30 June 2020 
MEETING WITH THE ENDOCRINE SOCIETY EDC ADVISORY GROUP 
COUNTERPART 
 
SANTE 
Commissioner Kyriakidis, 
ueller, (CAB-
Kyriakides) 
 (DG SANTE E2) 
WHERE, WHEN  Via videoconference, Tuesday 20 June 2020 
SUBJECT 
Endocrine Disruptors (EDs) 
OBJECTIVE OF  On request of the Endocrine Society as regards their position on the science of EDs 
THE MEETING 
and their regulation in the EU 
RESULT 
The Group presented themselves and the context in which they requested the meeting. 
In general they have been encouraged by the commitment given from Commissioner 
Kyriakidis on EDs and wish to offer their scientific expertise. They have already 
submitted comments to the Commission’s ED Fitness Check exercise and to the 
Chemicals Strategy roadmap. 
They presented a Powerpoint (see annex) putting forward their concerns on exposures 
to EDs and health effects, gaps in EU regulation and the need for immediate action to 
protect consumers. In particular they promoted inclusion of EDs in the EU Cancer Plan 
given links with prostate and breast cancers; the need to harmonise more sectors 
beyond pesticides and biocides including addressing food contact materials (FCMs) 
and cosmetic; and the links with increased vulnerability of immune-deficient 
individuals and other illnesses that may be linked with EDs during times of pandemic 
such as COVID-19. 
They emphasised the important aspects they consider on EDs such as low-dose, non-
monotonic effects and cumulative exposures. The impact on vulnerable populations 
including children, babies and pregnant women was also highlighted as were the roles 
that EDs can play in diseases such as cancer, growth issues, neurodevelopmental 
issues, diabetes and metabolic diseases, where they consider presence of EDs 
exacerbate the effects of diet, including for example sugar.  
They presented a table included in the report on EDs commissioned by the 
Parliament’s PETI committee for which Barbara Demeneix was an author, giving an 
overview of where they consider gaps in the current EU regulatory framework. They 
consider that classification in the CLP Regulation and thus identification would make 
it easier to regulate EDs in downstream legislation such as cosmetics and FCMs where 
they consider their presence unjustified. They consider EU action even more important 
in the global context, where third countries follow the EU approach. 
Commissioner Kyriakidis thanked the participants and that the Commission shares 
their ambitions for a horizontal and harmonised approach, which will be addressed 
under the Chemicals Strategy. In this respect, the Society was encouraged to also put 
across its views to Commissioners Sinkeviþius and Breton, who also have 
responsibility for this issue. Commissioner Kyriakidis agreed that EDs should be 
considered in the Cancer Plan and referred to the substantial additional budget set aside 


for the EU4Health initiative, which also focuses on non-communicable diseases. 
FOLLOW-UP 
Endocrine Society will aim to speak with Commissioner Breton (having already met 
Sinkeviþius) and were asked to send any more relevant information as soon as 
possible.
Annex  
Endocrine Society presentation  
+HDOWK&RPPLVVLR
6OLG
),1$/ 
2

Document Outline